Stockscreener 앱 받기
9.09
1.00%
0.13
전일 마감가:
$8.96
열려 있는:
$9.02
하루 거래량:
286.38K
Relative Volume:
0.74
시가총액:
$453.33M
수익:
-
순이익/손실:
$-108.30M
주가수익비율:
-2.8766
EPS:
-3.16
순현금흐름:
$-97.15M
1주 성능:
-7.65%
1개월 성능:
-26.54%
6개월 성능:
-22.05%
1년 성능:
+17.08%
1일 변동 폭
$8.75
$9.21
1주일 범위
$8.75
$9.96
52주 변동 폭
$7.39
$16.88
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
명칭
Kalvista Pharmaceuticals Inc
전화
(857) 999-0075
주소
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
KALV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| KALV | 9.11 | 453.33M | 0 | -108.30M | -97.15M | -3.16 |
| VRTX | 449.69 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.75 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.46 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.89 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.52 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2020-06-15 | 개시 | H.C. Wainwright | Buy |
| 2019-07-29 | 개시 | SVB Leerink | Outperform |
| 2019-03-20 | 개시 | Needham | Buy |
| 2018-10-30 | 개시 | Jefferies | Buy |
| 2018-09-21 | 개시 | Cantor Fitzgerald | Overweight |
| 2017-08-31 | 개시 | BTIG Research | Buy |
모두보기
Kalvista Pharmaceuticals Inc 주식(KALV)의 최신 뉴스
KalVista Pharmaceuticals' chief development officer sells shares for $66,572 By Investing.com - Investing.com Nigeria
Kalvista Pharmaceuticals CMO sells shares worth $74,765 - Investing.com India
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Insider Sells $74,793.02 in Stock - MarketBeat
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko Sells 14,400 Shares - MarketBeat
KalVista Pharmaceuticals' chief development officer sells shares for $66,572 - Investing.com
Kalvista Pharmaceuticals CMO sells shares worth $74,765 By Investing.com - Investing.com UK
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by First Turn Management LLC - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Share Price Crosses Below 50 Day Moving AverageTime to Sell? - MarketBeat
Insight into TANG CAPITAL MANAGEMENT LLC's Strategic Acquisition of KalVista Pharmaceuticals Inc Shares - GuruFocus.com
Suvretta Capital Management, LLC Increases Stake in KalVista Pha - GuruFocus.com
Vestal Point Capital, LP Increases Stake in KalVista Pharmaceuti - GuruFocus.com
Capital World Investors Expands Stake in KalVista Pharmaceuticals - GuruFocus.com
Objective long/short (KALV) Report - Stock Traders Daily
KalVista Pharma (KALV) to Present at Stifel and Jefferies Healthcare Conferences | KALV Stock News - StockTitan
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences - The Bakersfield Californian
Leerink Partnrs Has Bullish Estimate for KALV Q3 Earnings - MarketBeat
Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Citeline News & Insights
Jones Trading Initiates Coverage of KalVista Pharmaceuticals (KALV) with Buy Recommendation - MSN
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - BioSpace
KalVista Secures $184M Financing for Sebetralstat Launch - Yahoo Finance
KalVista prices $55M stock offering - MSN
Vanguard Group Inc's Strategic Acquisition in KalVista Pharmaceu - GuruFocus.com
KalVista sets pricing for $60 million stock offering By Investing.com - Investing.com Canada
KalVista Pharmaceuticals Shares Rise 11% on Royalty Financing Deal, Stock Offering - Marketscreener.com
U.S. Dollar/Moldova Lei (USDMDL) QuotePress Release - The Globe and Mail
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Gap UpHere's Why - MarketBeat
KalVista sets pricing for $60 million stock offering - Investing.com
DRI Healthcare Trust Announces Acquisition of a Synthetic Royalty Interest in the Worldwide Sales of Sebetralstat for the Treatment of Hereditary Angioedema Plus an Equity Investment in KalVista Pharmaceuticals - Barchart
Canadian Dollar/Australian Dollar (CADAUD) QuotePress Release - The Globe and Mail
KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million - Business Wire
KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust - Yahoo Finance
KalVista Pharmaceuticals, Inc. announced that it expects to receive $5 million in funding from DRI Capital Inc. - Marketscreener.com
Emerald Advisers LLC Purchases 192,091 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat
(KALV) Long Term Investment Analysis - Stock Traders Daily
Hereditary Angioedema Market Forecasted to Surge in Coming - openPR
sebetralstat shows promise in phase 3 HAE trial By Investing.com - Investing.com South Africa
sebetralstat shows promise in phase 3 HAE trial - Investing.com India
KalVista Pharmaceuticals Presents New Sebetralstat Data at the 2024 American College of Allergy Asthma and Immunology - The Bakersfield Californian
Hereditary Angioedema Market Size is Set for Rapid Growth as - openPR
(KALV) Trading Report - Stock Traders Daily
The Manufacturers Life Insurance Company Buys 3,314 Shares of KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - Defense World
KalVista Pharmaceuticals to Present Data at the 2024 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI) - Milton Daily Standard
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Short Interest Update - MarketBeat
Plasma Protease C1 Inhibitor Market Size, Development Growth, - openPR
(KALV) Technical Data - Stock Traders Daily
Marshall Wace LLP Has $576,000 Stock Position in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) - MarketBeat
Sweden Hereditary Angioedema Therapeutics Market Size & Outlook, 2030 - Grand View Research
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Stake Decreased by Dimensional Fund Advisors LP - MarketBeat
Kalvista shares hold Buy rating, price target on HAE study By Investing.com - Investing.com South Africa
Kalvista shares hold Buy rating, price target on HAE study - Investing.com
Kalvista Pharmaceuticals Inc (KALV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.80%
0.42%
자본화:
|
볼륨(24시간):